Written by HealthDay News
Updated on July 02, 2002
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, July 2, 2002 (HealthDayNews) -- National Cancer Institute (NCI) scientists say some molecular mechanisms may be common to hereditary and sporadic ovarian cancers.
In a study in tomorrow's issue of the Journal of the National Cancer Institute, researchers looked at mutations in BRCA1 and BRCA2 genes, which are tumor suppressor genes whose role in the functioning of cells includes repairing damaged DNA.
The scientists say they found that BRCA1 and BRCA2 gene mutations cause hereditary ovarian cancers through different pathways. However, they say those pathways may be similar to pathways at work in sporadic ovarian cancers.
Sporadic ovarian cancers are cases in which patients don't have a strong family history of that cancer.
The NCI scientists compared gene expression patterns of tumors from 61 people with ovarian cancer -- 18 with the BRCA1 mutation, 16 with the BRCA2 mutation, and 27 with sporadic ovarian cancer.
They analyzed about 6,500 genes and found 110 that were different between BRCA1 and BRCA2-associated ovarian tumors. However, they also found the gene expressions that separated BRCA1 and BRCA2-associated tumors were identified in two major groups of sporadic cancers.
For more information on ovarian cancer and the more than 100 tumor types it encompasses, visit Johns Hopkins University.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.